MA43283A - Procédés et compositions pour le traitement du cancer - Google Patents
Procédés et compositions pour le traitement du cancerInfo
- Publication number
- MA43283A MA43283A MA043283A MA43283A MA43283A MA 43283 A MA43283 A MA 43283A MA 043283 A MA043283 A MA 043283A MA 43283 A MA43283 A MA 43283A MA 43283 A MA43283 A MA 43283A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- compositions
- treatment
- methods
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001141—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/828—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562258134P | 2015-11-20 | 2015-11-20 | |
PCT/US2016/062865 WO2017087857A1 (fr) | 2015-11-20 | 2016-11-18 | Procédés et compositions pour le traitement du cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MA43283A true MA43283A (fr) | 2018-09-26 |
MA43283B1 MA43283B1 (fr) | 2022-08-31 |
Family
ID=58717878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA43283A MA43283B1 (fr) | 2015-11-20 | 2016-11-18 | Composition pour le traitement du cancer |
Country Status (19)
Country | Link |
---|---|
US (1) | US11033613B2 (fr) |
EP (2) | EP3377516B1 (fr) |
JP (3) | JP6991969B2 (fr) |
KR (1) | KR20180094922A (fr) |
CN (4) | CN116327903A (fr) |
AU (2) | AU2016356708B2 (fr) |
CA (1) | CA3005896A1 (fr) |
DK (1) | DK3377516T3 (fr) |
ES (1) | ES2926386T3 (fr) |
HR (1) | HRP20220994T1 (fr) |
HU (1) | HUE059694T2 (fr) |
LT (1) | LT3377516T (fr) |
MA (1) | MA43283B1 (fr) |
MD (1) | MD3377516T2 (fr) |
PL (1) | PL3377516T3 (fr) |
PT (1) | PT3377516T (fr) |
RS (1) | RS63561B1 (fr) |
SI (1) | SI3377516T1 (fr) |
WO (1) | WO2017087857A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
HRP20220994T1 (hr) | 2015-11-20 | 2022-11-11 | Memorial Sloan Kettering Cancer Center | Sastav za liječenje raka |
EP3458096A4 (fr) | 2016-05-18 | 2019-11-27 | Cue Biopharma, Inc. | Polypeptides multimères modulateurs des lymphocytes t et leurs procédé d'utilisation |
EP3468581A1 (fr) | 2016-06-13 | 2019-04-17 | Torque Therapeutics, Inc. | Méthodes et procédés pour favoriser la fonction des cellules immunitaires |
EP3548623A4 (fr) | 2016-11-30 | 2020-11-25 | Advaxis, Inc. | Compositions immunogènes ciblant des mutations récurrentes du cancer et leurs procédés d'utilisation |
IL297617B2 (en) | 2016-12-22 | 2023-11-01 | Cue Biopharma Inc | Multimeric polypeptides modulate T cells and methods for their use |
EP3565829A4 (fr) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation |
AU2018234628B2 (en) | 2017-03-15 | 2023-07-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
WO2019006401A2 (fr) * | 2017-06-30 | 2019-01-03 | Advaxis, Inc. | Compositions immunogènes à base de listeria comprenant des antigènes de protéine tumorale de wilms hétéroclitique et procédés d'utilisation correspondants |
AU2018328209A1 (en) | 2017-09-05 | 2020-04-23 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
CN111655714A (zh) * | 2017-11-08 | 2020-09-11 | 阿德瓦希斯公司 | 来自癌症相关蛋白的免疫原性异变肽及其使用方法 |
CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
WO2019173499A1 (fr) * | 2018-03-06 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 17-bêta-hydroxywithanolides et leur utilisation dans le traitement du cancer |
JP7393752B2 (ja) * | 2018-10-05 | 2023-12-07 | 株式会社癌免疫研究所 | 良性腫瘍の予防または治療薬 |
WO2020132297A1 (fr) | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation |
JP2022526011A (ja) * | 2019-04-10 | 2022-05-20 | エスエルエスジー リミテッド エルエルシー | 多価免疫療法組成物、wt1陽性癌を処置するための使用及び方法 |
WO2021138447A1 (fr) | 2019-12-31 | 2021-07-08 | Elixirgen Therapeutics, Inc. | Administration transitoire basée sur la température d'acides nucléiques et de protéines à des cellules et des tissus |
CN115666542A (zh) * | 2020-04-07 | 2023-01-31 | 梅塔诺伊治疗公司 | 用于治疗上皮性卵巢癌的乙醇胺调配物 |
EP4149534A4 (fr) | 2020-05-12 | 2024-09-04 | Cue Biopharma Inc | Polypeptides multimères modulateurs de lymphocytes t et leurs méthodes d'utilisation |
WO2022056014A1 (fr) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Polypeptides multimères modulateurs des lymphocytes t du cmh de classe ii pour le traitement du diabète sucré de type 1 (dt1) et leurs procédés d'utilisation |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5837249A (en) | 1985-04-19 | 1998-11-17 | The Wistar Institute | Method for generating an immunogenic T cell response protective against a virus |
WO1992013878A2 (fr) | 1991-02-07 | 1992-08-20 | Board Of Trustees Of The University Of Illinois | Produits mimetiques de conformation restreinte de tours beta et bombements beta, et peptides les contenant |
EP0771320A4 (fr) | 1993-07-29 | 1998-11-25 | Univ California | Leurres polynucleotidiques inhibant l'expression du complexe d'histocompatibilite majeure ii, et applications |
US5643786A (en) | 1995-01-27 | 1997-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for isolating dendritic cells |
CN1178956C (zh) | 1998-07-31 | 2004-12-08 | 杉山治夫 | 基于癌抑制基因wt1的产物的癌抗原 |
US7901693B2 (en) | 1998-09-30 | 2011-03-08 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7144581B2 (en) | 2000-10-09 | 2006-12-05 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7115272B1 (en) | 1998-09-30 | 2006-10-03 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7329410B1 (en) | 1998-09-30 | 2008-02-12 | Corixa Corporation | Compositions and method for WT1 specific immunotherapy |
US7655249B2 (en) | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
DE69938970D1 (de) * | 1998-09-30 | 2008-08-07 | Corixa Corp | Zusammensetzungen und verfahren für wt1-spezifische immunotherapie |
WO2001025273A2 (fr) | 1999-10-04 | 2001-04-12 | Corixa Corporation | Compositions et methodes se rapportant a une immunotherapie specifique a wt1 |
US20030082194A1 (en) | 2000-02-22 | 2003-05-01 | Alexander Gaiger | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
AU2003242305A1 (en) | 2002-06-12 | 2003-12-31 | Chugai Seiyaku Kabushiki Kaisha | Hla-a24-restricted cancer antigen peptide |
JP4566912B2 (ja) | 2003-06-27 | 2010-10-20 | 株式会社癌免疫研究所 | Wt1ワクチン適応患者の選択方法 |
EP1696027A4 (fr) | 2003-11-05 | 2008-05-14 | Int Inst Cancer Immunology Inc | Peptide antigene se liant a hla-dr d'origine wt1 |
US20060127409A1 (en) | 2003-12-01 | 2006-06-15 | Scheinberg David A | Bcr-abl vaccines and methods of use thereof |
CA2548135C (fr) | 2003-12-01 | 2014-04-22 | Sloan-Kettering Institute For Cancer Research | Analogues peptidiques synthetiques de liaison a l'antigene histocompatibilite et leurs utilisations |
WO2007047764A2 (fr) | 2005-10-17 | 2007-04-26 | Sloan Kettering Institute For Cancer Research | Peptides de liaison wt1 hla de classe ii, compositions et methodes associees comprenant ces peptides |
DE102006014261A1 (de) | 2006-03-28 | 2007-10-04 | Dr.Ing.H.C. F. Porsche Ag | Luftleitvorrichtung für ein Fahrzeug |
US9265816B2 (en) | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
CN101888852B (zh) | 2007-12-05 | 2017-02-08 | 株式会社癌免疫研究所 | 癌症疫苗组合物 |
US20110136141A1 (en) | 2009-12-03 | 2011-06-09 | Abbott Laboratories | Peptide reagents and method for inhibiting autoantibody antigen binding |
JP6282598B2 (ja) | 2012-01-13 | 2018-02-21 | メモリアル スローン ケタリング キャンサー センター | 免疫原性wt1ペプチド及びその使用方法 |
CA2898099A1 (fr) | 2013-01-15 | 2014-07-24 | David A. Scheinberg | Peptides wt-1 immunogenes et leurs procedes d'utilisation |
EP2762160A1 (fr) * | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Composition de vaccin contre le cancer peptidique WT1 pour administration mucosale |
AU2014228405B2 (en) * | 2013-03-15 | 2017-05-11 | The Trustees Of The University Of Pennsylvania | Cancer vaccines and methods of treatment using the same |
EA201690746A1 (ru) | 2013-10-25 | 2016-12-30 | Фармасайкликс Элэлси | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии |
JP2016540042A (ja) | 2013-11-05 | 2016-12-22 | コグネート バイオサービシズ, インコーポレイテッド | がんを処置するためのチェックポイント阻害剤および治療薬の組合せ |
US10835595B2 (en) | 2014-01-06 | 2020-11-17 | The Trustees Of The University Of Pennsylvania | PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy |
BR112016021345A8 (pt) * | 2014-03-17 | 2022-07-05 | Tapimmune Inc | Composições de vacina de molécula de ácido nucleico e usos das mesmas |
JP6515182B2 (ja) * | 2015-05-20 | 2019-05-15 | 大日本住友製薬株式会社 | Wt1抗原ペプチドおよび免疫調節剤の併用 |
HRP20220994T1 (hr) | 2015-11-20 | 2022-11-11 | Memorial Sloan Kettering Cancer Center | Sastav za liječenje raka |
-
2016
- 2016-11-18 HR HRP20220994TT patent/HRP20220994T1/hr unknown
- 2016-11-18 CN CN202210863762.9A patent/CN116327903A/zh active Pending
- 2016-11-18 CN CN202210863749.3A patent/CN115920017A/zh active Pending
- 2016-11-18 EP EP16867262.4A patent/EP3377516B1/fr active Active
- 2016-11-18 CN CN202210862167.3A patent/CN116327902A/zh active Pending
- 2016-11-18 PL PL16867262.4T patent/PL3377516T3/pl unknown
- 2016-11-18 DK DK16867262.4T patent/DK3377516T3/da active
- 2016-11-18 EP EP22175680.2A patent/EP4130026A1/fr active Pending
- 2016-11-18 US US15/777,514 patent/US11033613B2/en active Active
- 2016-11-18 CN CN201680077975.1A patent/CN108431022B/zh active Active
- 2016-11-18 CA CA3005896A patent/CA3005896A1/fr active Pending
- 2016-11-18 MA MA43283A patent/MA43283B1/fr unknown
- 2016-11-18 HU HUE16867262A patent/HUE059694T2/hu unknown
- 2016-11-18 AU AU2016356708A patent/AU2016356708B2/en active Active
- 2016-11-18 PT PT168672624T patent/PT3377516T/pt unknown
- 2016-11-18 ES ES16867262T patent/ES2926386T3/es active Active
- 2016-11-18 JP JP2018526090A patent/JP6991969B2/ja active Active
- 2016-11-18 LT LTEPPCT/US2016/062865T patent/LT3377516T/lt unknown
- 2016-11-18 MD MDE20180934T patent/MD3377516T2/ro unknown
- 2016-11-18 KR KR1020187017393A patent/KR20180094922A/ko not_active Application Discontinuation
- 2016-11-18 SI SI201631597T patent/SI3377516T1/sl unknown
- 2016-11-18 RS RS20220828A patent/RS63561B1/sr unknown
- 2016-11-18 WO PCT/US2016/062865 patent/WO2017087857A1/fr active Application Filing
-
2021
- 2021-12-08 JP JP2021198966A patent/JP2022033926A/ja active Pending
-
2022
- 2022-05-03 AU AU2022202973A patent/AU2022202973A1/en active Pending
-
2023
- 2023-12-27 JP JP2023220529A patent/JP2024041809A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20180339030A1 (en) | 2018-11-29 |
CN116327902A (zh) | 2023-06-27 |
RS63561B1 (sr) | 2022-10-31 |
JP2024041809A (ja) | 2024-03-27 |
CN108431022A (zh) | 2018-08-21 |
AU2022202973A1 (en) | 2022-05-26 |
AU2016356708A1 (en) | 2018-07-05 |
PL3377516T3 (pl) | 2022-10-10 |
LT3377516T (lt) | 2022-09-26 |
KR20180094922A (ko) | 2018-08-24 |
CN108431022B (zh) | 2022-08-09 |
AU2016356708B2 (en) | 2022-02-03 |
EP3377516A4 (fr) | 2019-06-26 |
CN116327903A (zh) | 2023-06-27 |
CA3005896A1 (fr) | 2017-05-26 |
EP3377516A1 (fr) | 2018-09-26 |
PT3377516T (pt) | 2022-09-23 |
EP3377516B1 (fr) | 2022-06-15 |
HRP20220994T1 (hr) | 2022-11-11 |
JP2018538265A (ja) | 2018-12-27 |
HUE059694T2 (hu) | 2022-12-28 |
MD3377516T2 (ro) | 2022-10-31 |
CN115920017A (zh) | 2023-04-07 |
JP6991969B2 (ja) | 2022-03-03 |
ES2926386T3 (es) | 2022-10-25 |
DK3377516T3 (da) | 2022-09-19 |
US11033613B2 (en) | 2021-06-15 |
WO2017087857A1 (fr) | 2017-05-26 |
SI3377516T1 (sl) | 2023-01-31 |
MA43283B1 (fr) | 2022-08-31 |
JP2022033926A (ja) | 2022-03-02 |
EP4130026A1 (fr) | 2023-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA41044A (fr) | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer | |
MA42420A (fr) | Vaccins pour le traitement et la prévention du cancer | |
MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
MA46427A (fr) | Compositions d'oligonucléotides et procédés associés | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
MA47613A (fr) | Compositions et procédés de traitement du cancer | |
MA51306A (fr) | Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
MA45675A (fr) | Méthodes et compositions permettant le traitement du cancer | |
DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
MA45429A (fr) | Polythérapie pour le traitement du cancer | |
MA41555A (fr) | Polythérapie pour le traitement du cancer | |
HK1247931A1 (zh) | 用於診斷和治療癌症的組合物和方法 | |
MA41123A (fr) | Polythérapie pour le traitement du cancer | |
MA47408A (fr) | Traitement du cancer | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
MA47172A (fr) | Compositions et procédés de traitement des inflammations intestinales et du cancer du côlon | |
SG11201702554QA (en) | Compositions and methods for the treatment of multiple sclerosis | |
FR3017298B1 (fr) | Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires | |
IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment |